A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Tepotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms VISION
- Sponsors EMD Serono; Merck KGaA
- 12 Mar 2018 Planned number of patients changed from 60 to 120.
- 25 Jan 2018 Planned number of patients changed from 120 to 60.
- 25 Jan 2018 Planned primary completion date changed from 30 Jun 2019 to 25 Jun 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History